- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01568736
B7 Coreceptor Molecules in Hyper IgD Syndrome Form of Mevalonate Kinase Deficiency (HIDS-MKD)
B7 Coreceptor Molecules as Clinically-Relevant Surrogate Biomarkers in the Hyper IgD Syndrome (HIDS) Form of Mevalonate Kinase Deficiency (MKD)
The hyper IgD syndrome (HIDS) is an inflammatory disease caused by mevalonate kinase deficiency. There is no cure, and available treatments of HIDS febrile episodes have shown limited clinical efficacy. The development of effective interventions for HIDS is limited by our poor understanding of the disease. The goal of the study is to better characterize the inflammatory response during HIDS episodes and to determine the relationship between this response and blood and urine markers of mevalonate kinase deficiency. This knowledge will help us learn more about the cause of the disease and should lead to the identification of new disease biomarkers that can be used to evaluate clinical efficacy in future therapeutic trials.
The primary hypothesis is that the costimulatory B7 glycoprotein abnormalities identified in the murine MKD model will be recapitulated in sera obtained from human HIDS patients, either before, during or after febrile episodes. The secondary hypothesis is that B7 glycoprotein molecule levels will correlate with clinical symptomatic severity score, other known biomarkers of HIDS, markers of inflammation and or markers of isoprenoid metabolism.
Study Overview
Status
Conditions
Study Type
Contacts and Locations
Study Locations
-
-
-
Nijmegen, Netherlands
- Radbound University of Nijmegen Medical Centre
-
-
-
-
Michigan
-
Houghton, Michigan, United States, 49931
- Michigan Techinical University
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- any race or ethnicity
- diagnosed with HIDS
Exclusion Criteria:
- parents' inability to donate blood
- currently having cancer, renal failure, diabetes, liver disease, thyroid diseases, major infectious diseases or immunodeficiency
- pregnancy
- inability to provide consent
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Immune System Diseases
- Immunoproliferative Disorders
- Disease
- Hematologic Diseases
- Genetic Diseases, Inborn
- Blood Protein Disorders
- Hereditary Autoinflammatory Diseases
- Metabolism, Inborn Errors
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Hypergammaglobulinemia
- Peroxisomal Disorders
- Syndrome
- Mevalonate Kinase Deficiency
Other Study ID Numbers
- STAIR 7003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyper IgD Syndrome
-
National Institute of Allergy and Infectious Diseases...CompletedImmunoproliferative DisorderUnited States
-
National Medical Research Center for Rehabilitation...Pirogov Russian National Research Medical University; DNKOM LLC; The Orenburg...RecruitingCardiovascular Diseases | Nervous System Diseases | Urologic Diseases | Diabetes | Neuromuscular Diseases | Hypercholesterolemia | Gout | Hyperbilirubinemia | Hyper IgE Syndrome | Hyper-LDL-cholesterolemia | Hyper Beta Lipoproteinemia | Hyper Eosinophilic SyndromeRussian Federation
-
Eunice Kennedy Shriver National Institute of Child...University of WashingtonUnknownWiskott-Aldrich Syndrome | Leukocyte Adhesion Deficiency Syndrome | X-Linked Agammaglobulinemia | X-Linked Hyper IgM SyndromeUnited States
-
Novartis PharmaceuticalsCompleted
-
National Institute of Allergy and Infectious Diseases...TerminatedAutosomal-dominant Hyper-IgE SyndromeUnited States
-
National Institute of Allergy and Infectious Diseases...TerminatedEctodermal Dysplasia | Hyper-IgM SyndromeUnited States
-
Bio Products LaboratoryCompletedCommon Variable Immunodeficiency | Primary Immune Deficiency Disorders | Hyper-IgM Syndrome | X-linked AgammaglobulinaemiaUnited States, United Kingdom, Hungary
-
Northwell HealthWithdrawnPolycystic Ovarian Syndrome (PCOS) | Patients Sensitive to Exogenous Gonadotropins | Ovarian Hyper Stimulation Syndrome (OHSS)United States
-
Otsuka Pharmaceutical Co., Ltd.CompletedHyper-low-density Lipoprotein (LDL) CholesterolemiaJapan
-
University of Nevada, Las VegasUniversity of Oklahoma; Oklahoma State UniversityCompletedMetabolic Syndrome | Hyper-LDL-cholesterolemiaUnited States